Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the same period last year.